Zacks: Analysts expect Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) to report earnings of -$0.40 per share

The brokerages expect Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSAGet a rating) will show ($0.40) earnings per share for the current quarter, Zacks reports. Two analysts released earnings estimates for Kiniksa Pharmaceuticals, with estimates ranging from ($0.52) to ($0.27). Kiniksa Pharmaceuticals reported earnings per share of ($0.72) in the same quarter last year, indicating a positive year-over-year growth rate of 44.4%. The company is due to release its next quarterly results on Monday, January 1.

On average, analysts expect Kiniksa Pharmaceuticals to report full year earnings of ($1.82) per share for the current year, with EPS estimates ranging from ($2.05) to ($1. $.58). For the next fiscal year, analysts expect the company to post earnings of ($1.40) per share, with EPS estimates ranging from ($1.55) to ($1.25). Zacks EPS averages are an average based on a survey of sell-side research companies that provide coverage for Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ: KNSAGet a rating) last released its quarterly earnings data on Tuesday, February 22. The company reported ($0.53) EPS for the quarter, missing Zacks consensus estimate of ($0.44) by ($0.09). The company posted revenue of $18.75 million for the quarter, versus a consensus estimate of $16.32 million.

A number of analysts have commented on KNSA’s actions. Bank of America cut its price target on Kiniksa Pharmaceuticals shares from $37.00 to $34.00 and set a “buy” rating for the company in a Wednesday, Dec. 29 report. Zacks Investment Research cut shares of Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a Thursday, Feb. 24 research note.

KNSA Stock traded down $0.59 in midday trading on Monday, hitting $10.82. The company’s stock had a trading volume of 324,515 shares, compared to an average volume of 352,428. The stock has a market capitalization of $747.71 million, a PE ratio of -4.70 and a beta of -0.02. Kiniksa Pharmaceuticals has a fifty-two week low of $9.05 and a fifty-two week high of $17.71. The company’s 50-day moving average price is $10.43.

Several large investors have recently bought and sold shares of KNSA. Invesco Ltd. bought a new position in shares of Kiniksa Pharmaceuticals during Q2 for a value of approximately $153,000. Morgan Stanley increased its position in Kiniksa Pharmaceuticals shares by 115.5% during the second quarter. Morgan Stanley now owns 383,934 shares of the company worth $5,348,000 after purchasing an additional 205,803 shares during the period. M&T Bank Corp increased its position in Kiniksa Pharmaceuticals shares by 88.3% during the third quarter. M&T Bank Corp now owns 20,501 shares of the company worth $234,000 after purchasing an additional 9,611 shares during the period. SG Americas Securities LLC bought a new position in shares of Kiniksa Pharmaceuticals during Q3 for a value of approximately $211,000. Finally, M&G Investment Management Ltd. bought a new position in Kiniksa Pharmaceuticals stock during Q3 worth approximately $1,568,000. 43.01% of the shares are held by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile (Get a rating)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, is focused on the discovery, acquisition, development and commercialization of therapeutic drugs for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that has completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in a Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibiting the CD40-CD154 interaction, a T-cell co-stimulatory signal essential for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Recommended Stories

Get a Free Copy of Zacks’ Research Report on Kiniksa Pharmaceuticals (KNSA)

For more information on Zacks Investment Research’s research offerings, visit

Earnings history and estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Get news and reviews for Kiniksa Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Kiniksa Pharmaceuticals and related companies with’s FREE daily newsletter.